Medtronic Advances Lumenless Defibrillation Lead for Conduction Pacing

Cardiac rhythm management, electrophysiology, and implantable medical device applications increasingly focus on therapies that align with the heart’s natural electrical conduction. Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of its OmniaSecure defibrillation lead, enabling its use in conduction system pacing (CSP) via placement in the left bundle branch (LBB) area.

FDA Approval Extends Lead Placement to Left Bundle Branch Area
The approval allows the OmniaSecure lead to be positioned in the LBB area, supporting conduction system pacing that more closely replicates physiological cardiac activation. This represents a shift from traditional pacing approaches that may not fully align with the heart’s natural conduction pathways.

The lead connects to implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), enabling treatment of ventricular tachyarrhythmias, ventricular fibrillation, and bradyarrhythmias while also providing pacing functionality.

Lumenless Design Supports Precise and Reliable Delivery
The OmniaSecure lead features a lumenless construction, meaning it does not contain an internal hollow channel. This design supports catheter-based delivery and contributes to structural durability and reliability.

With a diameter of 4.7 French (1.66 mm), it is among the smallest defibrillation leads available, enabling placement in anatomically sensitive regions such as the LBB area. The design is based on established pacing lead technology previously approved for conduction system pacing, ensuring compatibility with existing clinical approaches.

Combined Defibrillation and Physiologic Pacing Capabilities
By enabling conduction system pacing, the lead allows stimulation of the heart’s intrinsic conduction network, supporting more synchronous ventricular activation. This can help reduce complications associated with non-physiological pacing methods.

The system also supports advanced therapy configurations such as left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), which combines conduction system pacing with left ventricular pacing to improve synchronisation in selected patients.

Clinical Evidence Demonstrates Safety and Performance
The approval is supported by data from the LEADR LBBAP clinical study, which evaluated the lead’s performance in LBB area pacing. Reported results showed a defibrillation success rate of 100% at implantation and a major complication rate of 2.1% at three months.

These results indicate that the lead can deliver both effective defibrillation therapy and reliable pacing when positioned in the conduction system, supporting its use in clinical practice.

Integration with Existing Cardiac Device Ecosystems
The OmniaSecure lead is designed for use with transvenous ICD and CRT-D systems, enabling integration into existing cardiac rhythm management workflows. It can also be combined with additional leads in biventricular or hybrid pacing configurations, depending on patient requirements.

This compatibility supports flexibility in treatment planning, allowing clinicians to tailor therapy based on individual patient conditions and device configurations.

Comparison with Conventional Defibrillation Leads
Conventional defibrillation leads are typically designed for placement in the right ventricle and may not support conduction system pacing. They often rely on designs that prioritise defibrillation without enabling physiologic pacing approaches.

In contrast, the OmniaSecure lead combines defibrillation capability with the option for LBB-based conduction system pacing in a single device. Its lumenless design and reduced diameter also differentiate it from traditional leads, supporting more precise placement and expanded therapeutic options.

By integrating defibrillation and physiologic pacing into a single lead platform, the OmniaSecure system reflects ongoing developments in cardiac rhythm management aimed at improving synchronisation, safety, and treatment outcomes.

Edited by Natania Lyngdoh, Induportals Editor — Adapted by AI.

www.medtronic.com